预后指数在外周 T细胞淋巴瘤-非特指型预后判断中的应用价值

Prognostic Significance of PIT in Unspecified Peripheral T-cell Lymphoma

目的评价外周T细胞淋巴瘤-非特指型(PTCL-U)预后指数(PIT)在PTCL-U预后判断中的价值。方法分析2005年5月—2008年5月间61例经免疫组化方法复检确诊的PTCL-U患者的临床资料,按PIT的预后不良因素个数将61例患者分成4组,分析各组患者对治疗的反应及其预后的差异。结果预后不良因素等级与首程化疗的疗效有关(χ2=8.154,P=0.043),4组总的生存率经Log-rank检验差异显著(P=0.0498)。4组的中位生存时间(MST)分别为:36+、16.61、13.16、11.98个月。4组的1年总生存(OS)分别为85.66%、68.44%、44.62%、33.25%;2年OS分别为53.75%、39.11%、29.75%、16.62%。影响预后的不良因素多因素分析结果表明,PIT评分(P=0.043)可以作为PTCL-U的独立预后因素,而PIT中单一指标尚不能作为独立的预后因素。结论PIT能够在一定程度上预测PTCL-U对治疗的反应性和预后。

Objective To evaluate the Prognostic significance of prognostic index （PIT） for peripheral T - cell lymphoma -unspecified （PTCL-U） in judgment of PTCL-U prognosis. Methods The data of 61 PTCL-U patients, diagnosed by immunohistochemistry re - examination from May 2005 to May 2008, were divided into 4 groups according to numbers of poor prognostic factors to analyze the difference of response to treatment and prognosis. Results Poor prognostic factors were related to the effect of first treatment （X^2 = 8. 154, P = 0. 043 ） , and there was significant difference in overall survival detected by Log Rank between4 groups （P = 0.0498）. The median survival time （MST） of 4 groups was 36^＋ , 16.61, 13.16, 11.98 months, respectively. The 1 - year overall survivals （OS） were 85.66% , 68.44% , 44. 62% , 33.25% , respectively, and 2 - year were 53.75%, 39. 11%, 29. 75%, 16.62%, respectively. Multivariate survival analysis showed that PIT scores （P = 0. 043 ） could be used as independent prognostic factors, but a single index of PIT could not be used as a prognostic factor. Conclusion PIT can predict the response of PTCL - C to treatment and its prognosis.